Prevalence of tobacco use in selected Johannesburg suburbs

J. A. Teare*, N. Naicker, P. Albers, A. Mathee

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

3 Citations (Scopus)


Background. Tobacco smoking is estimated to kill more than 44 000 South Africans every year. Studies have shown that since the introduction of tobacco control measures, national smoking prevalence has declined in South Africa (SA). Objective. To determine the prevalence of tobacco smoking over a 7-year period in five impoverished neighbourhoods in Johannesburg, SA. Methods. Data were collected through the annual administration of a prestructured questionnaire to one adult respondent in preselected dwellings from 2006 to 2012. Information was collected on socioeconomic status, smoking practices and health status. Results. Over the 7-year period of the analysis, smoking levels remained unchanged. The proportion of households with one or more smokers varied significantly across the five study neighbourhoods. Approximately 20% of households in Hillbrow and as many as 77% in Riverlea had a member who smoked. Conclusions. Despite a national downward trend in smoking levels, tobacco use remains high and persistent in certain vulnerable communities, requiring scaled-up action to reduce the risk of a range of tobacco-related diseases.

Original languageEnglish
Pages (from-to)40-44
Number of pages5
JournalSouth African Medical Journal
Issue number1
Publication statusPublished - Jan 2018

Bibliographical note

Funding Information:
The ACERCA study was sponsored by the Spanish Society of Nephrology (S.E.N.) with an unrestricted grant from Roche Pharma Spain. AMC declare that has received research support from Amgen, Abbott, Boehringer-Ingelheim and Roche, as well as honoraria for participating in advisory boards from Abbvie, Amgen, Boehringer-Ingelheim, Esteve, Janssen-Cilag, Novartis and Roche. AC has received research support from Amgen and Roche. He has received honoraria for participating in advisory boards from Roche, Amgen, Pfizer, Novartis, Abbott, Astra-Zeneca and received speaker fees from Roche, Amgen, Johnson and Johnson, Bristol Myers Squibb, Novartis, Pfizer, Almirall, Esteve, Astra-Zeneca, Siemens. Others authors declare that they have no competing interests.

Publisher Copyright:
© 2018, South African Medical Association. All rights reserved.


  • Tobacco smoking
  • Johannesburg
  • South Africa


Dive into the research topics of 'Prevalence of tobacco use in selected Johannesburg suburbs'. Together they form a unique fingerprint.

Cite this